⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
CD137 Targeted Therapy Research Report 2026-2030: 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global & Regional Clinical & Commercial Trends,
globenewswire.com
GILD
BMY
REGN
MRK
PFE
ABBV
BIIB
AZN
AMGN
NVS
GMAB
ABL
BNTX
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
globenewswire.com
GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
globenewswire.com
GMAB
Genmab Announces Topline Results for Epcoritamab (DuoBody ® CD3xCD20) from Phase 3 EPCORE ® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
businesswire.com
GMAB
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
globenewswire.com
GMAB
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
GMAB
Genmab Portfolio Prioritization Update
businesswire.com
GMAB
Genmab Portfolio Prioritization Update
globenewswire.com
GMAB
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
prnewswire.com
GTBP
REGN
GMAB
AUTL
LYEL